Savient Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Savient Pharmaceuticals, Inc. (SVNT)

Q2 2012 Earnings Call

August 08, 2012 09:00 a.m. ET

Executives

Louis Ferrari – President and Chief Executive Officer

Richard Crowley – EVP, Biopharmaceutical Operations

Philip Yachmetz – SVP, General Counsel

Kenneth Bahrt – SVP, Chief Medical Officer

David Gionco – Chief Accounting Officer

Analysts

Eric Schmidt – Cowen and Company

Cory Kasimov – JP Morgan

Katherine Xu – William Blair

David Krempa – Morning Star

Tazeen Ahmad – Bank of America

Rahul Jasuja – Noble Financial

Carol Werther – Summer Street Research

Heather Behanna – JMP Securities

Presentation

Operator

Good day ladies and gentlemen, and thank you for standing by. Welcome to the Savient Pharmaceuticals second quarter 2012 financial results conference call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session. As a reminder this conference will be recorded.

I would now like to introduce your host for today, Mr. Philip Yachmetz, Senior Vice President and General Counsel for Savient Pharmaceuticals. Sir, please begin.

Philip Yachmetz

Thank you and good morning. Welcome to Savient Pharmaceuticals second quarter 2012 financial results conference call. This morning we issued a press release providing financial results and highlights for the second quarter of 2012. The press release is available on our website at www.savient.com.

Before today’s call, I would like to read our Safe Harbor statement. Comments made during this conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Savient Pharmaceuticals.

If you liked this article you might like

Here's How to Trade Bank of America, Freeport-McMoRan, Seagate Right Now

5 Stocks Under $10 Set to Soar

5 Biotech Stocks Under $10 Making Big Moves

5 Names Seeing Bullish Flow

Arena Pharmaceuticals And 6 More Stocks To Watch